The new timeline was revealed during an R&D update yesterday during which the French drugmaker also said it has the capacity to make a billion doses of the vaccine each year.
The phase 1/2 trial of the recombinant protein-based vaccine – which uses GlaxoSmithKline’s AS03 adjuvant and is based on Sanofi’s baculovirus expression system already used in its quadrivalent flu vaccine – could get “full approval by the first half of 2021”, according to the company.
The new schedule suggests a dramatic acceleration from Sanofi’s initial timeframe for the project when it was announced back in February, which started out with the objective of clinical trials starting in 2021…
